Bis­pe­cif­ic M&A reach­es As­traZeneca; Count­down for Mer­ck­'s big bid; Biotech buy­out in sav­age times; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Thanks to the short week, we have a lighter edi­tion and few­er sto­ries to re­cap — but the news is no less in­ter­est­ing, and some might just sur­prise you.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER